You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Programming Metabolically Fit TILs for Immunotherapy

    SBC: LIPO-IMMUNO TECH LLC            Topic: NCI

    ABSTRACT Advances in molecular biology and genetic engineering have led to the design and use of modified T cells recognize tumors to achieve significant tumor control upon adoptive cell transfer (ACT) to patients. These T cells are either transduced with tumor antigen reactive T cell receptors (TCR), or chimeric antigen receptors (CARs). Recently, a surge in studies with neo-antigen reactive T ce ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Portable, affordable, quantitative microchip electrophoresis for hemoglobin A1C testing

    SBC: HEMEX HEALTH INC            Topic: 200

    PROJECT SUMMARY Diabetes is one of the most important health issues in the world. The number of people living with diabetes has quadrupled since 1980, with the greatest increase in prevalence in low and middle-income countries. Not only is diabetes a major cause of morbidity and mortality, but it can also devastate the finances of families and strain countries’ financial resources. World Health ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  3. Development of SP-A Derived Peptidomimetics for the Treatment of Asthma- Phase II

    SBC: RaeSedo, LLC            Topic: NHLBI

    Current treatments for asthma, while reducing exacerbations in a subset of patients by focusing on airway inflammation, do not eliminate them. Asthma exacerbations are a significant cause of morbidity and mortality in asthma as they can lead to airway injury, lung function decline and death. Exacerbations in more severe asthmatics are of particular concern, as health care costs and lost productivi ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  4. Critical angle reflection imaging for label-free quantification of molecular interactions

    SBC: BIOSENSING INSTRUMENT INC            Topic: 400

    TITLE: Critical angle reflection imaging (CARi) for label-free quantification of molecular interactions SUMMARYMeasuring molecular interactions of proteins are critical for understanding protein functions and cellular processes, for discovery and validating biomarkers, and for developing and screening drugs. In particular, membrane proteins play key roles in many cellular functions and are the lar ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Affordable sialoglycans and associated reagents for expanded chemoenzymatic production

    SBC: Integrated Micro-Chromatography Systems, Inc.            Topic: 300

    Project Summary Sialoglycans are sialic acid-containing oligosaccharides that play important biological roles in human biology and pathology and are indispensable molecular probes for research related to bacterial and viral infection, cancer metastasis, immune regulation, etc. The multifaceted functions of sialoglycans in human milk are also being explored. Nevertheless, sialoglycan-related resear ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Development of peptide nucleic acid antibiotics

    SBC: NUBAD LLC            Topic: NIAID

    The world is rapidly heading towards a pre-1940’s scenario when it comes to fighting infectious disease. Antimicrobial resistance is a growing problem on a global scale, greatly hampering our abilities to quell worldwide epidemics such as influenza, SARS, COVID-19, tuberculosis and malaria, as well as the simple staphylococcus infection. Unless innovative strategies are developed to produce robu ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  7. Aminoglycosides with reduced ototoxicity

    SBC: NUBAD LLC            Topic: NIAID

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well-known antibiotics in clinical use for over 70 years, but one of the major limitations in their use is their ototoxicity. We are developing fast and low-cost methods to develop aminoglycosides with anti-ribosomal activities and reduced toxicity. In this project, we will identify novel aminoglycoside antibacterials, that show reduced ot ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  8. Chitosan Endoluminal Hemostatic Dressing

    SBC: Tricol Biomedical Inc            Topic: 400

    AbstractPost-operative bleeding remains the major complication of transurethral and open prostatic surgical procedures. Prolonged bleeding from these procedures causes delayed healing and longer hospitalization which significantly increases the cost of patient care. Moreover, prolonged urethral catheterization due to significant post-operative hematuria is one of the major causes of discomfort and ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  9. eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis

    SBC: AQUALUNG THERAPEUTICS, CORP            Topic: NHLBI

    ABSTRACT The development of radiation-induced lung injury (RILI) is a potentially fatal toxicity in cancer patients undergoing thoracic radiotherapy or in individuals exposed to ionizing radiation (IR) from a nuclear incident. The pathobiology of radiation pneumonitis and radiation-induced lung fibrosis (RILF) is complex but includes the deleterious effects of unchecked inflammation (reactive oxyg ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  10. Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma

    SBC: Faknostics, LLC            Topic: 102

    Abstract Melanoma is the deadliest form of skin cancer, affecting an estimated 1.2 million Americans. The disease has a high propensity for dissemination, and metastatic melanoma has a dismal prognosis, with a median survival of only 5–8 months. Healthcare costs for melanoma in 2021 are projected to reach nearly $4 billion, with a rising incidence rate. Despite considerable efforts in recent yea ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government